HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ZVRA
Zevra Therapeutics, Inc.
ZVRA's fundamentals are strong: revenue grew 75% and its operating margin went from −104% to 61%. At 9.2x earnings, it's trading below its usual 11x. Analysts expect that strong growth to continue, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ZVRA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
ZVRA's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ZVRA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.4x | $7.75 | -31% |
| Current | 9.2x | $11.16 | — |
| Fair | 11x | $13.47 | +21% |
| Forward | 14x | $11.16 | — |
| Expensive | 24x | $28.69 | +157% |
Historical ranges are pointers, not guarantees.
ZVRA's PE is in its fair range at 9.2x. On analysts' estimates for next year's earnings, today's price would be 14x, in its expensive range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ZVRA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
ZVRA has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ZVRA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.82 | -32% |
| Q3 2026 | $1.21 | +227% |
| Q2 2026 | $0.94 | +$1.25 |
| Q1 2026 | $2.01 | +$4.01 |
| Q4 2025 | $1.35 | +$3.69 |
| Q3 2025 | $0.37 | +$2.37 |
| Q2 2025 | -$0.31 | +$1.40 |
| Q1 2025 | -$2.00 | -$0.62 |
| Q4 2024 | -$2.34 | -$1.02 |
ZVRA has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ZVRA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $37.8M | +45% |
| Q2 2026 | $39.7M | +53% |
| Q1 2026 | $36.2M | +78% |
| Q4 2025 | $34.1M | +183% |
| Q3 2025 | $26.1M | +605% |
| Q2 2025 | $25.9M | +482% |
| Q1 2025 | $20.4M | +496% |
| Q4 2024 | $12M | -8.9% |
ZVRA's revenue has grown year over year for seven quarters in a row: $38M last quarter, up 45% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 31% | +15 points |
| Q2 2026 | 42% | +317 points |
| Q1 2026 | 144% | +170 points |
| Q4 2025 | 27% | +155 points |
| Q3 2025 | 16% | +755 points |
| Q2 2025 | -274% | +260 points |
| Q1 2025 | -26% | +572 points |
| Q4 2024 | -128% | -17 points |
ZVRA has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
ZVRA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $9.8M | +136% |
| Q2 2026 | $16.8M | +$20.6M |
| Q1 2026 | $6.1M | +$14.4M |
| Q4 2025 | $5.5M | +$21.8M |
| Q3 2025 | $4.2M | +$22.3M |
| Q2 2025 | -$3.8M | +$15.3M |
| Q1 2025 | -$8.3M | +$7.8M |
| Q4 2024 | -$16.3M | -$20K |
ZVRA's free cash flow has turned positive after six years mostly in the red: $38M over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ZVRA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ZVRA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +396K shares |
| 1 year | +10% | +5.8M shares |
| 3 years | +78% | +27M shares |
| 5 years | +75% | +26.5M shares |
| Available history | +3231% | +59.9M shares |
ZVRA has 62M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | $3.4M |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ZVRA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.3x | Net Cash |
| Q2 2026 | -1.7x | Net Cash |
| Q4 2021 | -14.1x | Net Cash |
| Q3 2021 | -17.3x | Net Cash |
| Q2 2021 | -15.3x | Net Cash |
| Q1 2021 | -14.1x | Net Cash |
ZVRA has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ZVRA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.9 | Neutral |
| Stochastic | 45.9 | Neutral |
ZVRA's weekly RSI is 51 (neutral) and its Stochastic is 46 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ZVRA PE vs Healthcare Sector
| Metric | ZVRA | Sector median | Relative |
|---|---|---|---|
| PE | 9.2x | 26x | 64% below |
| PE % | 40 | 29 | 11 pts above |
ZVRA is trading at 9.2x earnings, a 64% discount to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ZVRA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.7 | 4.8% above |
| 20 week MA | $11.3 | 1.5% below |
| 50 week MA | $10.4 | 7.3% above |
| 100 week MA | $9.66 | 16% above |
| 200 week MA | $7.72 | 45% above |
ZVRA has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
ZVRA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.69 | $11.5 | +72% |
| 2021 | $11.5 | $8.97 | -22% |
| 2022 | $8.97 | $4.29 | -52% |
| 2023 | $4.29 | $6.55 | +53% |
| 2024 | $6.55 | $8.39 | +28% |
| 2025 | $8.39 | $8.87 | +5.7% |
| 2026 YTD | $8.87 | $11.2 | +26% |
ZVRA has the edge over HIMS on returns for 2026, with the stronger performance.